Subjects: Library Science，Information Science >> Library Science submitted time 2024-05-08
Abstract： Purposes Based on combing the science of science theories related to scientific journals, this paper constructs a five-force model of the influence of scientific journals and proposes paths and strategies to enhance the influence of scientific journals. Methods Using methods such as literature research, in-depth interviews, and conceptual analysis, the journal influence five-force model is constructed from the aspects of scientific knowledge production, flow, and dissemination, and then countermeasures and suggestions are put forward. Findings It is proposed that the influence of scientific journals includes five aspects: knowledge power, persuasion power, management power, expression power, and dissemination power. These five aspects are used to construct the five-force model of the influence of scientific journals. Conclusions The formation and enhancement of the influence of scientific journals is a systematic project. It can be approached by applying the theory of knowledge activities to enhance the knowledge power of scientific journals; promoting academic exchanges to improve the persuasion power of scientific journals; paying attention to the construction of the talent team to enhance the management power of scientific journals; leveraging the advantages of structural holes to demonstrate the expressive power of scientific journals; fully recognizing the functions of journals to strengthen the dissemination power of scientific journals.
Subjects: Medicine, Pharmacy >> Clinical Medicine submitted time 2023-01-09 Cooperative journals: 《中国全科医学》
Abstract：
Background The incidence of colorectal cancer is high, and metastatic colorectal cancer (mCRC) has entered a new era of target immunotherapy. At present, there are rare reports on the efficacy and safety of PD-1 inhibitors combined with fuquitinib compared with fuquitinib alone.Objective To observe the efficacy and adverse reactions of fuquitinib combined with PD-1 inhibitor in the treatment of third-line and above metastatic colorectal cancer. Methods The clinical data of 75 patients with metastatic colorectal cancer treated in our hospital from June 2020 to March 2022 were collected and analyzed retrospectively. They were divided into two groups according to different treatment regimens: fuquantinib group (n = 28) and PD-1 inhibitor combined with fuquitinib group (n = 47). The main outcome measures were objective response rate (ORR), disease control rate (DCR), median progression-free survival time (PFS) and adverse reactions in the two groups. Results As of the last follow-up, the ORR of the single-drug group and the combined group were 7.1% and 14.9%, respectively, and there was no significant difference (P=0.528); the DCR was 67.9% and 89.4%, respectively, and there was a statistically significant difference in DCR between the two groups (P=0.021). The median PFS time of monotherapy group was 4.5 months (95% CI:3.0~6.0), and the median PFS time of combination group was 6.4 months (95% CI:5.3~7.5). There was significant difference in PFS between the two groups.In addition, the median survival time of different types of PD-1 inhibitors was analyzed, and the results showed that there was no significant difference in PFS among different types of PD-1 inhibitors combined with fuquitinib.The adverse reactions of the two groups were mainly grade 1-2. Compared with the single drug group, the incidence of hypothyroidism in the combined treatment group was significantly higher than that in the single drug group (P=0.043). In addition, there was no significant difference in the incidence of other adverse reactions between the two groups (P＞0.05). Conclusion Compared with fuquitinib alone, PD-1 inhibitor combined with fuquitinib has longer survival time and lower incidence of severe adverse reactions in patients with metastatic colorectal cancer, so it is an effective and safe treatment.
Hits
YES
Hits
Downloads
Comment